Mode
Text Size
Log in / Sign up

Enteral immunonutrition reduces infectious complications in patients undergoing surgery for colorectal cancerSpecial nutrition may lower infection risk after colorectal cancer surgery

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider enteral immunonutrition to reduce infectious complications following colorectal cancer surgery.

This systematic review and meta-analysis evaluated the impact of enteral immunonutrition on outcomes following surgery for colorectal cancer (CRC) in 1,198 patients across 9 studies. The primary finding indicates that enteral immunonutrition is associated with a reduced incidence of infectious complications (OR: 0.48; 95% CI: 0.34 to 0.66; P < 0.001). This association is supported by the meta-analysis of randomized controlled trials.

Secondary outcomes, including anastomotic leakage, ileus, and length of stay (LOS), did not show statistically significant associations with enteral immunonutrition. Specifically, anastomotic leakage showed an OR of 0.56 (95% CI: 0.31 to 1.03; P = 0.063), while ileus showed an OR of 0.74 (95% CI: 0.44 to 1.24; P = 0.249). The mean difference for LOS was -0.78 (95% CI: -2.02 to 0.47; P = 0.222).

Clinically, these findings suggest that while enteral immunonutrition may be beneficial for reducing infection rates in CRC surgical patients, it does not appear to influence other common postoperative metrics like anastomotic leakage or hospital stay duration. No specific limitations were reported by the authors.

How this fits prior evidence

This finding addresses a gap in managing perioperative complications for colorectal cancer surgery. While previous coverage has focused on systemic therapies such as PD-1/PD-L1 inhibitors for metastatic disease and the role of AI in diagnosis, this meta-analysis specifically addresses nutritional interventions to reduce postoperative infectious complications.

Surgery for colorectal cancer is a major milestone in a patient's journey. One of the biggest hurdles during recovery is managing complications like infections. New data suggests that a specific type of nutrition, called enteral immunonutrition, might help keep patients safer during this critical time.

Researchers looked at 1,198 patients across nine different studies to see how this nutritional approach worked. They found that patients who received enteral immunonutrition had a significantly lower risk of developing infectious complications after their surgery. This suggests the nutrition may help the body stay stronger against germs while healing.

However, the findings are specific. While it helped with infections, the study did not find that this nutritional plan changed other common outcomes like anastomotic leakage (a leak at the surgical site), ileus (a temporary bowel blockage), or the total length of time spent in the hospital. It is a targeted benefit for infection prevention rather than a general fix for all recovery hurdles.

What this means for you:
Enteral immunonutrition can reduce infection risks after colorectal cancer surgery but does not shorten hospital stays.

Common questions

Does this nutrition help with all surgical complications?

No, it specifically helps with infections. The study found that while enteral immunonutrition reduced the risk of infectious complications, it did not have a significant effect on other issues like anastomotic leakage, ileus, or the total length of time spent in the hospital.

Who is this finding for?

This finding applies to patients undergoing surgery for colorectal cancer. The data comes from a review of 1,198 patients across nine different studies to see how enteral immunonutrition impacts their recovery.

Does it help patients get home from the hospital faster?

The study did not find a significant link between enteral immunonutrition and a shorter length of stay in the hospital. While it helps fight infections, it does not appear to change how many days a patient stays in the hospital.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedJun 2026
View Original Abstract ↓
ObjectiveEnteral immunonutrition is extensively administered to patients who have undergone colorectal cancer (CRC) surgery. However, its efficacy in reducing postoperative complications and the length of hospital stay (LOS) remains controversial. The aims of our meta-analysis were to investigate the effects of enteral immunonutrition on postoperative complications in patients undergoing CRC surgery.MethodsWe searched the PubMed, Web of Science, and Wanfang databases from January 2000 to December 2025 and the reference lists of selected randomized controlled trials (RCT) The odds ratio (OR), weighted mean difference (WMD) and 95% confidence interval (CI) were used to assess the association between enteral immunonutrition and postoperative complications in patients undergoing CRC surgery.ResultsNine studies involving 1,198 patients with CRC were identified. Our results demonstrated that enteral immunonutrition could reduce the incidence of infectious complications 95% CI among postoperative CRC patients (OR: 0.48; 95% CI: 0.34–0.66; P < 0.001). The results of the subgroup analysis revealed that both preoperative enteral immunonutrition and postoperative enteral immunonutrition could reduce the incidence of postoperative infectious complications in CRC patients. Furthermore, our results revealed that enteral immunonutrition was not associated with postoperative anastomotic leakage (OR: 0.56; 95% CI: 0.31–1.03; P = 0.063), ileus (OR: 0.74; 95% CI: 0.44–1.24; P = 0.249), or LOS (WMD = −0.78; 95% CI: −2.02 to 0.47; P = 0.222), and we found no associations between enteral immunonutrition and anastomotic leakage, ileus and LOS in patients who underwent CRC surgery.ConclusionsEnteral immunonutrition could reduce the incidence of infectious complications in patients undergoing CRC surgery. However, it did not reduce the incidence of postoperative anastomotic leakage or ileus and did not shorten LOS of patients who underwent CRC surgery.Research registration unique identifying number (UIN)The study protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO) under registration number CRD420261288947.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/view/CRD420261288947, identifier: CRD420261288947.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.